ProCE Banner Activity

CME

New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

In this interactive recording of a live CCO Webinar, a dynamic expert panel discusses the latest data on optimal use of immune checkpoint inhibitors and antibody–drug conjugates for treating patients with early-stage through metastatic TNBC.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: January 22, 2021

Expiration: January 21, 2022

No longer available for credit.

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for oncologists and other healthcare providers who care for patients with triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate available data on the use of ICI-based combinations as part of neoadjuvant/adjuvant therapy for early-stage triple-negative breast cancer
  • Plan first-line treatment with ICI-based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune-targeted therapies with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune checkpoint inhibitors in patients with breast cancer
  • Recommend ongoing clinical trials assessing new therapeutic approaches for appropriate patients with triple-negative breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH, has disclosed that she has received funds for research support from Bristol-Myers Squibb and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Genomic Health, Merck, Pfizer, and Puma.

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS, has disclosed that his spouse/partner has ownership interest in and has received salary from Grail and that he has received consulting fees from Amgen, AstraZeneca, Eisai, Lilly, Merck, Novartis, Pfizer, and Seattle Genetics and funds for research support paid to his institution from Acetylon, Amgen, Calithera, CytomX, Genentech/Roche, Immunomedics, Incyte, Lilly, Novartis, Pfizer, Seattle Genetics, and Zentalis.

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Rita Nanda, MD, has disclosed that she has received consulting fees from Aduro, Athenex, Clovis, Daiichi Sankyo, Genentech, Immunomedics, MacroGenics, Merck, Pfizer, and Seattle Genetics; funds for research support from AstraZeneca, Celgene, Corcept, Genentech/Roche, Immunomedics, Merck, OBI, Odonate, Pfizer, and Seattle Genetics; and other financial or material support from G1 Therapeutics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 22, 2021, through January 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence and performance of learners to integrate immune checkpoint inhibitors into the treatment of triple-negative breast cancer.